Monte Rosa Therapeutics, Inc. (GLUE) total assets
Monte Rosa Therapeutics, Inc. (GLUE) had total assets of $448.66M at the end of fiscal 2025 (December 31, 2025). That is 2.3% higher than the $438.73M of fiscal 2024. Figures as of 18 Nov 2026, 04:05 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total assets, fiscal 2025
- $448.66M
- Change on fiscal 2024
- +2.3%
- Growth, 5 years
- +55.5% a year
- Highest on record
- $448.66Mfiscal 2025
- Lowest on record
- $49.38Mfiscal 2020
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Monte Rosa Therapeutics, Inc. total assets, in more detail
Over the five fiscal years to 2025 total assets grew at a compound 55.5% a year. Across the 6 fiscal years on record (2020–2025), the highest was $448.66M in fiscal 2025 and the lowest $49.38M in fiscal 2020.
Total assets by fiscal year
Monte Rosa Therapeutics, Inc. total assets, year by year
| Fiscal year | Total assets | Change | Year ended |
|---|---|---|---|
| 2025 | $448.66M | 2.3% up | |
| 2024 | $438.73M | 44.4% up | |
| 2023 | $303.76M | 11.3% down | |
| 2022 | $342.39M | 6.5% down | |
| 2021 | $366.33M | 641.9% up | |
| 2020 | $49.38M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.
How to read it
It measures the resources the business has put to work; assets that grow faster than profit mean each new unit of investment is earning less.
Monte Rosa Therapeutics, Inc., figure by figure
- Monte Rosa Therapeutics, Inc. market cap
- Monte Rosa Therapeutics, Inc. revenue
- Monte Rosa Therapeutics, Inc. earnings
- Monte Rosa Therapeutics, Inc. earnings per share (EPS)
- Monte Rosa Therapeutics, Inc. P/E ratio
- Monte Rosa Therapeutics, Inc. P/S ratio
- Monte Rosa Therapeutics, Inc. P/B ratio
- Monte Rosa Therapeutics, Inc. free cash flow
- Monte Rosa Therapeutics, Inc. operating margin
- Monte Rosa Therapeutics, Inc. dividend
- Monte Rosa Therapeutics, Inc. shares outstanding
- Monte Rosa Therapeutics, Inc. total debt
- Monte Rosa Therapeutics, Inc. cash on hand
- Monte Rosa Therapeutics, Inc. return on equity (ROE)
- Monte Rosa Therapeutics, Inc. return on invested capital (ROIC)
Monte Rosa Therapeutics, Inc. (GLUE) overview: price, valuation and scorecard
Monte Rosa Therapeutics, Inc. total assets: questions and answers
How large are Monte Rosa Therapeutics, Inc.'s total assets?
Monte Rosa Therapeutics, Inc. (GLUE) had total assets of $448.66M at the end of fiscal 2025 (December 31, 2025). That is 2.3% higher than the $438.73M of fiscal 2024.
What is the growth rate of Monte Rosa Therapeutics, Inc.'s total assets?
Over the five fiscal years to 2025 total assets grew at a compound 55.5% a year.
What are the highest and lowest total assets figures on record for Monte Rosa Therapeutics, Inc.?
Across the 6 fiscal years on record (2020–2025), the highest was $448.66M in fiscal 2025 and the lowest $49.38M in fiscal 2020.
How is Monte Rosa Therapeutics, Inc.'s total assets calculated?
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.
Fiscal years are named for the calendar year they end in.
Learn: total assets
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Monte Rosa Therapeutics, Inc. (GLUE) total assets”, data as of 18 November 2026. https://funkfolio.com/stock/GLUE/total-assets
Underlying data: the company's filings with the SEC and Yahoo Finance.